Sugi Predict

Sugi Predict / Compounds / SCHEMBL320357

SCHEMBL320357

SCHEMBL320357

CCOC(=O)c1c[nH]cc(-c2ccccc2)c1=O

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ TSHR P16473 2/20 0.53
▸ MAPT P10636 5/20 0.50
▸ CLEC4M Q9H2X3 1/20 0.50
▸ NPSR1 Q6W5P4 1/20 0.49
▸ ADORA3 P0DMS8 1/20 0.49
▸ GABRA1 P14867 1/20 0.48
▸ GABRB1 P18505 1/20 0.48
▸ GABRA3 P34903 1/20 0.48
▸ GABRB2 P47870 1/20 0.48
▸ ALDH1A1 P00352 5/20 0.48
▸ SMN1; SMN2 Q16637 4/20 0.48
▸ HPGD P15428 2/20 0.48
▸ RAB9A P51151 2/20 0.47
▸ PDE3B Q13370 1/20 0.47
▸ PDE3A Q14432 1/20 0.47
▸ JAK2 O60674 1/20 0.47
▸ JAK3 P52333 1/20 0.47
▸ NPC1 O15118 1/20 0.47
▸ NFKB1 P19838 1/20 0.47
▸ NFKB2 Q00653 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4042415 0.89 TSHR (0.58) TSHRMAPTNPSR1ADORA3ALDH1A1
SCHEMBL15334383 0.88 ALDH1A1 (0.50) TSHRMAPTCLEC4MGABRA1GABRB1
SCHEMBL18832216 0.86 GABRA1 (0.54) TSHRMAPTCLEC4MGABRA1GABRB1
SCHEMBL15334465 0.86 SMN1; SMN2 (0.49) CLEC4MALDH1A1SMN1; SMN2HPGDRAB9A
SCHEMBL699308 0.86 PRKCZ (0.49) TSHRMAPTCLEC4MALDH1A1SMN1; SMN2
SCHEMBL15333820 0.84 JAK2 (0.53) TSHRMAPTCLEC4MNPSR1GABRA1
SCHEMBL15333999 0.83 JAK2 (0.53) TSHRMAPTCLEC4MNPSR1GABRA1
SCHEMBL7439372 0.81 KMT2A (0.61) TSHRMAPTCLEC4MGABRA1GABRB1
SCHEMBL11551710 0.80 TSHR (0.50) TSHRMAPTNPSR1ALDH1A1SMN1; SMN2
SCHEMBL5089650 0.78 JAK2 (0.52) TSHRMAPTCLEC4MGABRA1GABRB1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3299369-B1 PYRIDO-AZAHETERECYDIC COMPOUND AND PREPARATION METHOD AND USE THEREOF SHANGHAI INST MATERIA MEDICA CAS (CN) 2020-11-11 — — EP disclosed
EP-3299369-B1 PYRIDO-AZAHETERECYDIC COMPOUND AND PREPARATION METHOD AND USE THEREOF SHANGHAI INST MATERIA MEDICA CAS (CN) 2020-11-11 — — EP disclosed
CN-107709320-B Pyrido-nitrogen heterocyclic compound and preparation method and application thereof 中国科学院上海药物研究所 2020-11-06 — — CN disclosed
US-10710996-B2 Pyrido-azaheterecydic compound and preparation method and use thereof SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF SCIENCES (CN) 2020-07-14 — — US disclosed
US-10710996-B2 Pyrido-azaheterecydic compound and preparation method and use thereof SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF SCIENCES (CN) 2020-07-14 — — US disclosed
US-20180244667-A1 PYRIDO-AZAHETERECYDIC COMPOUND AND PREPARATION METHOD AND USE THEREOF SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF SCIENCES (CN) 2018-08-30 — — US disclosed
EP-3299369-A1 PYRIDO-AZAHETERECYDIC COMPOUND AND PREPARATION METHOD AND USE THEREOF Shanghai Institute of Materia Medica, Chinese Academy of Sciences (CN) 2018-03-28 — — EP disclosed
EP-2810937-B1 PYRIDONE DERIVATIVE DAIICHI SANKYO CO LTD (JP) 2016-11-30 — — EP disclosed
WO-2016184434-A1 PYRIDO-AZAHETERECYDIC COMPOUND AND PREPARATION METHOD AND USE THEREOF 中国科学院上海药物研究所 2016-11-24 — — WO disclosed
US-8933103-B2 Pyridone derivatives DAIICHI SANKYO COMPANY, LIMITED (JP) 2015-01-13 — — US disclosed
EP-2810937-A1 PYRIDONE DERIVATIVE DAIICHI SANKYO COMPANY, LIMITED (JP) 2014-12-10 — — EP disclosed
US-20130281428-A1 Pyridone Derivatives DAIICHI SANKYO COMPANY, LIMITED (JP) 2013-10-24 — — US disclosed
EP-2590968-A1 CYCLIC ETHER COMPOUNDS USEFUL AS KINASE INHIBITORS Novartis AG (CH) 2013-05-15 — — EP disclosed
US-20130109682-A1 CYCLIC ETHER COMPOUNDS USEFUL AS KINASE INHIBITORS NOVARTIS AG (CH) 2013-05-02 — — US disclosed
US-20130109682-A1 CYCLIC ETHER COMPOUNDS USEFUL AS KINASE INHIBITORS NOVARTIS AG (CH) 2013-05-02 — — US disclosed
US-20130109682-A1 CYCLIC ETHER COMPOUNDS USEFUL AS KINASE INHIBITORS NOVARTIS AG (CH) 2013-05-02 — — US disclosed
WO-2012004217-A1 CYCLIC ETHER COMPOUNDS USEFUL AS KINASE INHIBITORS NOVARTIS AG (CH) 2012-01-12 — — WO disclosed
WO-2012004217-A1 CYCLIC ETHER COMPOUNDS USEFUL AS KINASE INHIBITORS NOVARTIS AG (CH) 2012-01-12 — — WO disclosed
US-6333336-B1 GAMMA-AMINOBUTYRIC ACID RECEPTORS AS ANTICONVULSANTS FORMING THE COMPOUND BY AMIDATION MERCK SHARP & DOHME LTD. (GB) 2001-12-25 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130281428-A1 Pyridone Derivatives AXL, PDXK, TYRO3 TSHR 60/4885MAPT 2219/4885CLEC4M 2290/4885
US-20130109682-A1 CYCLIC ETHER COMPOUNDS USEFUL AS KINASE INHIBITORS PIM1, GSK3A, GSK3B TSHR 4240/4885MAPT 2904/4885CLEC4M 3803/4885
US-20180244667-A1 PYRIDO-AZAHETERECYDIC COMPOUND AND PREPARATION METHOD AND USE THEREOF MET, MERTK, DMPK TSHR 3370/4885MAPT 2878/4885CLEC4M 1842/4885
US-10710996-B2 Pyrido-azaheterecydic compound and preparation method and use thereof MET, MERTK, DMPK TSHR 3370/4885MAPT 2878/4885CLEC4M 1842/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.